Drug Profile
PLB 1003
Alternative Names: PLB1003Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Beijing Pearl Biotechnology
- Class Antineoplastics
- Mechanism of Action Anaplastic lymphoma kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer in China (PO)
- 15 Dec 2021 Phase-I development is ongoing in China (PO) (NCT03130881)
- 08 Nov 2016 Phase-I clinical trials in Non-small cell lung cancer in China (PO) (NCT03130881)